

TRANSMITTAL FORM

IFW

Application Serial Number	10/524,539
Filing Date	September 28, 2005
First Named Inventor	Ranjeny THOMAS
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket No.	23558-006US
Patent No.	Not applicable
Issue Date	Not applicable

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) <input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]	<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> CD(s) for large table or computer program <input type="checkbox"/> Amendment After Allowance	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <input type="checkbox"/> Appeal Brief (in triplicate) <input type="checkbox"/> Status Inquiry <input type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Petition for Extension of Time (1/2/3 months) <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above		

CORRESPONDENCE ADDRESS


Direct all correspondence to: PATENT ADMINISTRATOR
Proskauer Rose LLP
1001 Pennsylvania Ave., N.W.
Suite 400
Washington, D.C. 2004
Tel. No.: (202) 416-6800
Fax No.: (202) 416-6899
CUSTOMER NO: 61263

SIGNATURE BLOCK

Date: September 28, 2006
Reg. No.: 40,244
Tel. No.: (202) 416-6800
Fax No.: (202) 416-6899

Respectfully submitted,

Paul M. Booth
Attorney for the Applicant(s)
Proskauer Rose LLP
1001 Pennsylvania Ave., N.W.
Suite 400
Washington, D.C. 20004



Attorney Docket No.: 23558-006US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ranjeny THOMAS, et al. Confirmation No.: 1436
Appl. No.: 10/524,539 Examiner: Unassigned
Filing Date: September 28, 2005 Art Unit: Unassigned
Title: IMMUNOMODULATING COMPOSITIONS, PROCESSES FOR THEIR
PRODUCTION AND USES THEREFOR

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Listed on the attached Form PTO/SB/08A are documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 CFR §1.56. Enclosed for the Examiner's convenience is a copy of the listed foreign document (abstract only), a Communication from the EPO (dated 03/30/2006) and the European Search Report. These materials are being submitted to comply with the provisions of 37 CFR §1.97-§1.98.

The citation of any document herewith, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

U.S. Serial No.: 10/524,539

Attorney Docket No.: 23558-006US



CONCLUSION

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "P. Booth", written over a horizontal line.

By

Paul M. Booth
Attorney for Applicant
Registration No. 40,244
Customer No. 61263

Date: September 28, 2006

PROSKAUER ROSE LLP
1001 Pennsylvania Avenue, N.W.
Suite 400
Washington, DC 20004
Telephone: (202) 416-6800
Facsimile: (202) 416-6899
CUSTOMER NO: 61263

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/524,539
Filing Date	September 8, 2005
First Named Inventor	Ranjeny Thomas
Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	23558-006US

Sheet 2 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		E. Martin, et al., "Antigen-Specific Suppression of a Primed Immune...", , Univ of Queensland, Princess Alexandra Hospital, XP-002347198, pg. 1, Brisbane, Queensland, AU.	
		E. Martin, et al., "Inhibition of Relb Function in Dendritic Cells Induces Antigen-Specific Toleranc in Vivo", CICR, XP-002347199, pg. 1, Brisbane, AU.	
		B.J. O'Sullivan, et al., "Keeping T Cells At Bay: Inhibition of NFkB...", XP-002372797, pg 1, Univ of Queensland, Pricess Alexandra Hospital, Brisbane, Queensland, Australia.	
		B.J. O'Sullivan, et al., "Maturation and Function of Human Dendritic Cells Can Be Controlled By Relb", XP-002372798, page 1, Centre for Immunology and Cancer Research.	
		Monika Haas,et al., "Effect of proteasome inhibitors on monocytic I kB-a...", XP-000857509, March 1998, pp. 395-404, Vol. 63, Journal of Leukocyte Biology.	
		J.X. Gao, et al., "CD40-deficient dendritic cells producing interleukin-10,... rejection", Immunology, 1999, pp. 159-170, Vol. 98, Blackwell Science Ltd.	
		Giuseppe Penna, et al., "1-a,25-Dihydroxyvitamin D3, Inhibits...Cell Activation", The Journal of Immunology, 2000, pp. 2405-2411 The American Association of Immunologists.	
		Satomichi Yoshimura, et al., "Role of NFkB in antigen presentation...PSI", Journal of Immunology, 2001, pp. 1883-1893, Vol. 31, Wiley-Vch Verlag GmbH, Weinheim, Germany	
		Georg A. Hollander, et al., "Induction of alloantigen-specific mice", Immunology, 1996, pp. 4994-4998, Vol. 93, Proc. Natl. Acad. Sci. USA.	
		Brendan J. O'Sullivan, et al., "RelB nuclear translocation regulates...function", PNAS, XP-002347201,2000, pp. 11421-11426, Vol. 97, Centre for Immunology & Cancer Resrch, AU.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/524,539
Filing Date	September 8, 2005
First Named Inventor	Ranjeny Thomas
Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	23558-006US

Sheet 3

of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Clifford M. Snapper, et al., "B Cells Lacking RelB Are...Switching", The XP-002347202, Journal of Experimental Medicine, 1996, pp. 1537-1541, Vol. 184	
		Angus G. Thompson, et al., "T Cells Signaled by Nf-kB...Activation", The Journal of Immunology, 2004, pp. 1671-1680, The American Association of Immunologists, Inc.	
		Jang-Ik Lee, et al., "Cyclosporine a Inhibits...Dendritic Cells", XP-000984802, Transplantation, 1999, pp. 1255-1263, Vol. 68, No. 9, Lippincott Williams & Wilkins, Inc.	
		Ling Zhou, et al., "Inhibition of the CD40 Pathway...Triazolopyrimidine", XP-002277919, Clinical Immunology, 1999, pp. 232-238, Vol. 93, Academic Press	
		Ela Martin, et al., "Antigen-Specific Suppression of a Primed Immune... Interleukin-10", XP-002347203, Immunity, 2003, pp. 155-167, Vol. 18, Cell Press	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.